Shames, David S.

First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer

Horn, L., Mansfield, A. S., Szczęsna, A., Havel, L., Krzakowski, M., Hochmair, M. J., Huemer, F., Losonczy, G., Johnson, M. L., Nishio, M., et al. (2018) · New England Journal of Medicine

Lung Cancer Research StudiesCancer Immunotherapy and Biomarkers

Cited by 3,586

Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

Mok, T., Wu, Y.-L., Lee, J. S., Yu, C.-J., Sriuranpong, V., Sandoval-Tan, J., Ladrera, G., Thongprasert, S., Srimuninnimit, V., Liao, M., et al. (2015) · Clinical Cancer Research

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 468

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): An international, multicentre, single-arm, phase 2 trial

Rosell, R., Dafni, U., Felip, E., Curioni-Fontecedro, A., Gautschi, O., Peters, S., Massutí, B., Palmero, R., Aix, S. P., Carcereny, E., et al. (2017) · The Lancet Respiratory Medicine

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 182

Neuregulin-1-Mediated Autocrine Signaling Underlies Sensitivity to HER2 Kinase Inhibitors in a Subset of Human Cancers

Wilson, T. R., Lee, D. Y., Berry, L., Shames, D. S., & Settleman, J. (2011) · Cancer Cell

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 161

CDKN2A/p16 Inactivation Mechanisms and Their Relationship to Smoke Exposure and Molecular Features in Non–Small-Cell Lung Cancer

Tam, K. W., Zhang, W., Soh, J., Stastny, V., Chen, M., Sun, H., Thu, K., Rios, J. J., Yang, C., Marconett, C. N., et al. (2013) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 109

Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations

Klughammer, B., Brugger, W., Cappuzzo, F., Ciuleanu, T., Mok, T., Reck, M., Tan, E. H., Delmar, P., Klingelschmitt, G., Yin, A.-Y., et al. (2016) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 98

Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors

Juric, D., Dienstmann, R., Cervantes, A., Hidalgo, M., Messersmith, W., Blumenschein, G. R., Tabernero, J., Roda, D., Calles, A., Jimeno, A., et al. (2015) · Clinical Cancer Research

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 59